Alan G. Olivero

2.9k total citations
26 papers, 618 citations indexed

About

Alan G. Olivero is a scholar working on Genetics, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Alan G. Olivero has authored 26 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 9 papers in Molecular Biology and 7 papers in Organic Chemistry. Recurrent topics in Alan G. Olivero's work include Glioma Diagnosis and Treatment (13 papers), Cancer Genomics and Diagnostics (6 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Alan G. Olivero is often cited by papers focused on Glioma Diagnosis and Treatment (13 papers), Cancer Genomics and Diagnostics (6 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Alan G. Olivero collaborates with scholars based in United States, Spain and France. Alan G. Olivero's co-authors include Dieter Seebàch, Beat Weidmann, Laurent Salphati, Jodie Pang, Leo Widler, Daniel Kirchhofer, Charles Eigenbrot, Christopher D. Maycock, Patrick Y. Wen and Timothy F. Cloughesy and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Alan G. Olivero

26 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan G. Olivero United States	13	312	200	160	89	73	26	618
Jong Sung Koh South Korea	17	542 1.7×	284 1.4×	130 0.8×	196 2.2×	63 0.9×	36	923
Stéphanie Blanchard Singapore	12	323 1.0×	166 0.8×	118 0.7×	166 1.9×	76 1.0×	29	548
Christoph M. Dehnhardt United States	18	641 2.1×	312 1.6×	106 0.7×	135 1.5×	31 0.4×	22	938
Anthony D. William Singapore	16	378 1.2×	341 1.7×	261 1.6×	271 3.0×	183 2.5×	25	922
Renaud Prudent France	18	687 2.2×	186 0.9×	78 0.5×	188 2.1×	26 0.4×	37	1.1k
F. Gessier Switzerland	16	559 1.8×	329 1.6×	95 0.6×	213 2.4×	45 0.6×	25	897
Kirk Robarge United States	19	664 2.1×	370 1.9×	76 0.5×	143 1.6×	78 1.1×	26	1.0k
Bernard Barlaam United Kingdom	17	448 1.4×	306 1.5×	63 0.4×	256 2.9×	49 0.7×	40	811
Brendan Frett United States	20	493 1.6×	531 2.7×	47 0.3×	190 2.1×	53 0.7×	53	1.0k
Harish Nagaraj Singapore	7	190 0.6×	103 0.5×	113 0.7×	134 1.5×	74 1.0×	8	365

Countries citing papers authored by Alan G. Olivero

Since Specialization

Citations

This map shows the geographic impact of Alan G. Olivero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan G. Olivero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan G. Olivero more than expected).

Fields of papers citing papers by Alan G. Olivero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan G. Olivero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan G. Olivero. The network helps show where Alan G. Olivero may publish in the future.

Co-authorship network of co-authors of Alan G. Olivero

This figure shows the co-authorship network connecting the top 25 collaborators of Alan G. Olivero. A scholar is included among the top collaborators of Alan G. Olivero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan G. Olivero. Alan G. Olivero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Salphati, Laurent, Jodie Pang, Bruno Alicke, et al.. (2024). Preclinical characterization of the absorption and disposition of the brain penetrant PI3K/mTOR inhibitor paxalisib and prediction of its pharmacokinetics and efficacy in human. Xenobiotica. 54(2). 64–74. 5 indexed citations

Wen, Patrick Y., John de Groot, James Battiste, et al.. (2022). CTNI-27. MULTI-CENTER, PHASE 2 STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND PRELIMINARY EFFICACY OF PAXALISIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH UNMETHYLATED GLIOBLASTOMA (GBM). Neuro-Oncology. 24(Supplement_7). vii76–vii77. 1 indexed citations

Wen, Patrick Y., John de Groot, James Battiste, et al.. (2021). Abstract LB125: Pharmacokinetics of paxalisib in phase 2 clinical study in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status. Cancer Research. 81(13_Supplement). LB125–LB125. 3 indexed citations

Ellingson, Benjamin M., Jingwen Yao, Catalina Raymond, et al.. (2020). Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clinical Cancer Research. 26(13). 3135–3144. 10 indexed citations

Wen, Patrick Y., John de Groot, James Battiste, et al.. (2020). Abstract CT205: Phase 2 study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K / mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status. Cancer Research. 80(16_Supplement). CT205–CT205. 2 indexed citations

Wen, Patrick Y., Timothy F. Cloughesy, Alan G. Olivero, et al.. (2016). A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.. Journal of Clinical Oncology. 34(15_suppl). 2012–2012. 10 indexed citations

Salphati, Laurent, Sheerin Shahidi-Latham, Kai Barck, et al.. (2014). Distribution of the Phosphatidylinositol 3-Kinase Inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 Intracranial Glioblastoma Models—Assessment by Matrix-Assisted Laser Desorption Ionization Imaging. Drug Metabolism and Disposition. 42(7). 1110–1116. 36 indexed citations

Salphati, Laurent, Jodie Pang, Emile G. Plise, et al.. (2012). Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human. Drug Metabolism and Disposition. 40(9). 1785–1796. 30 indexed citations

Staben, Steven T., Nicole Blaquière, Vickie Tsui, et al.. (2012). Cis-Amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase. Bioorganic & Medicinal Chemistry Letters. 23(3). 897–901. 5 indexed citations

10.

Salphati, Laurent, Jodie Pang, Emile G. Plise, et al.. (2011). Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. Xenobiotica. 41(12). 1088–1099. 20 indexed citations

11.

Hansen, Joshua D., Jonas Grina, M. Bruce Welch, et al.. (2010). Non-oxime pyrazole based inhibitors of B-Raf kinase. Bioorganic & Medicinal Chemistry Letters. 21(11). 3488–3492. 38 indexed citations

12.

Folkes, Adrian, Stewart Baker, Irina Chuckowree, et al.. (2008). The discovery of GDC-0941: A potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. Cancer Research. 68. 5 indexed citations

13.

Hansen, Joshua D., Jonas Grina, Brad Newhouse, et al.. (2008). Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorganic & Medicinal Chemistry Letters. 18(16). 4692–4695. 57 indexed citations

14.

Olivero, Alan G., Charles Eigenbrot, Richard Goldsmith, et al.. (2005). A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo. Journal of Biological Chemistry. 280(10). 9160–9169. 36 indexed citations

15.

Lazarus, Robert A., Alan G. Olivero, Charles Eigenbrot, & Daniel Kirchhofer. (2004). Inhibitors of Tissue Factor • Factor VIIa for Anticoagulant Therapy. Current Medicinal Chemistry. 11(17). 2275–2290. 39 indexed citations

16.

Shahrokh, Zahra, Eric Wai Ming Lee, Alan G. Olivero, et al.. (1998). Stability of alkoxycarbonylamidine prodrugs.. Pharmaceutical Research. 15(3). 434–441. 7 indexed citations

17.

Robarge, Kirk, Michael S. Dina, Todd C. Somers, et al.. (1998). Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists. Bioorganic & Medicinal Chemistry. 6(12). 2345–2381. 11 indexed citations

18.

Blackburn, Brent, et al.. (1997). From Peptide to Non-Peptide. 3. Atropisomeric GPIIbIIIa Antagonists Containing the 3,4-Dihydro-1H-1,4-benzodiazepine-2,5-dione Nucleus. Journal of Medicinal Chemistry. 40(5). 717–729. 47 indexed citations

19.

Olivero, Alan G., Beat Weidmann, & Dieter Seebàch. (1981). Enantioselective Addition of Chiral Organotitanium Derivatives to Aldehydes. Helvetica Chimica Acta. 64(7). 2485–2488. 33 indexed citations

20.

Weidmann, Beat, Leo Widler, Alan G. Olivero, Christopher D. Maycock, & Dieter Seebàch. (1981). Selectivities in the Reactions of Alkyl‐, Aryl‐ and Heterosubstituted Organotitanium Compounds Preliminary Communication. Helvetica Chimica Acta. 64(1). 357–361. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact